Form 4: Centessa Pharma CTO Exercises, Sells Shares
Insider Transaction Report
Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, exercised stock options and subsequently sold shares totaling 49,792 ordinary shares over two days.
Summary
- Tia L. Bush, Centessa Pharmaceuticals' Chief Technology & Quality Officer, engaged in two separate transactions involving the exercise of stock options and subsequent sale of ordinary shares.
- On September 9, 2025, Bush exercised options to acquire 24,792 ordinary shares at an exercise price of $8.01 per share.
- Immediately following, on September 9, 2025, she sold all 24,792 shares at a price of $20.00 per share.
- On September 10, 2025, Bush exercised options to acquire an additional 25,000 ordinary shares at an exercise price of $9.42 per share.
- Concurrently, on September 10, 2025, she sold all 25,000 shares at a price of $22.00 per share.
- Both sales were conducted under a Rule 10b5-1 trading plan established on September 14, 2024.
- Following these transactions, Bush directly beneficially owns 121,503 ordinary shares.
Sentiment
Score: 6
Explanation: The transactions represent a routine exercise of options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. While the officer profited from the sales, the reduction in direct ownership is a neutral event, often for personal financial management, and not necessarily indicative of a change in company outlook.
Positives
- The officer exercised options, indicating the options were in-the-money and providing a personal financial gain.
- The sales were executed at significantly higher prices ($20.00 and $22.00) than the exercise prices ($8.01 and $9.42), demonstrating a profitable transaction for the officer.
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned, rather than reactive, sale.
Negatives
- The officer sold a substantial number of shares (49,792 total), which could be interpreted as a reduction in direct ownership stake, although it is common for officers to sell shares acquired through option exercises for liquidity or tax purposes.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Industry Context
This filing is a routine insider transaction report and does not provide broader industry context. It reflects an individual executive's personal financial planning rather than a strategic company move.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-Fact | Gregory Weinhoff | Raphael Deferiere | 2025-08-11 | Appointment of a substitute attorney-in-fact with full power of substitution for executing SEC filings on behalf of several individuals, including Tia L. Bush. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Delegation | Gregory Weinhoff, an existing attorney-in-fact, appointed Raphael Deferiere as a substitute attorney-in-fact to execute SEC filings (Forms 3, 4, 5, Schedule 13D/G, Form 144) for several listed individuals, including Tia L. Bush. This ensures continuity and flexibility in compliance filings. | 2025-08-11 | Enhances administrative efficiency for SEC compliance filings for key personnel by providing an additional authorized signatory. |
Stakeholder Impact
- Shareholders: The sale of shares by a key executive could be viewed with slight caution, though the pre-planned nature mitigates concerns. The transactions themselves do not directly impact company operations or strategy.
- Employees: No direct impact mentioned.
Next Steps
- Continued vesting of remaining share options for Tia L. Bush.
Key Dates
| Date | Description |
|---|---|
| 2022-05-20 | 25% of shares subject to a share option vested and became exercisable. |
| 2024-03-01 | First installment of 1/48th of shares subject to a share option vested and became exercisable. |
| 2024-09-14 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-08-11 | Date of Substitute Power of Attorney appointment. |
| 2025-09-09 | Date of option exercise and sale of 24,792 ordinary shares. |
| 2025-09-10 | Date of option exercise and sale of 25,000 ordinary shares. |
| 2025-09-11 | Date of Form 4 signature. |
| 2031-05-07 | Expiration date of a share option. |
| 2034-02-01 | Expiration date of a share option. |
Recommendation
holdThe filing details routine insider transactions (option exercises and sales) conducted under a pre-established 10b5-1 trading plan. These transactions are primarily for personal financial management and do not signal a change in the company's fundamental prospects or an immediate shift in management's confidence. Therefore, the filing itself does not provide a basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this information.
Keywords
Centessa Pharmaceuticals, CNTA, Tia L. Bush, Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.